A purple and pink letter v on a white background.
February 10, 2020

How ARTAS iX™ Can Grow Your Hair Restoration Business

According to the International Society of Hair Restoration Surgery (ISHRS) 2017 Practice Census —the most recent data available—more than 635,000 hair restoration procedures were performed in 2016 alone, establishing a 60% increase in total hair restoration procedures over previous data gathered in 2014. Additionally, there was a 67% increase in surgical procedures. A 2019 report by Global Market Insights, Inc., a global market research and management consulting company, predicted the global hair transplantation market will surpass a market value of $31.0 billion by 2025.

The level of demand for hair restoration shows steady growth with strong opportunities for new hair restoration businesses; something worth capitalizing on right away. With the right equipment, hair restoration treatments are a lucrative market for medical aesthetic professionals. While there are a range of surgical and non-surgical hair restoration procedures in the market, ARTAS iX™ certainly stands out. Discover what sets  ARTAS apart and how this could benefit your medical aesthetics business.

Start with the Basics: What Is FUE?

Minimally invasive hair restoration procedures can generally be divided into two methods based on how hair follicles are removed from the donor site. These two methods are follicular unit transplantation (FUT) and follicular unit extraction (FUE).  

Both methods remove hair follicles from the donor area along the back and side of the head, but FUT procedures use a scalpel to surgically remove a strip of hair from the back of the head before dividing it into follicular units to be implanted in the recipient site(s). In comparison, typical FUE procedures extract donor hair follicles in naturally occurring groups of generally one to three hairs. The grafts are then sorted by the number of hairs they each contain and implanted at the natural angle they would grow in the scalp, allowing for greater customization during implantation, and a more natural-looking outcome.  

Although FUT can be effective, it is a much more invasive procedure that results in a linear scar and often causes more discomfort during post-operative recovery. FUE, on the other hand, is minimally invasive, omitting the need for donor-site suture removal and resulting in a shorter recovery time. According to that same Global Market Insights report  noted earlier, market demand is moving in favor of the FUE transplantation method, with a compound annual growth rate (CAGR) from 2019 to 2025 of 28%. In 2018 alone, FUE procedures accounted for 34.3%  of the global hair services market.

Discover the Device: What Is ARTAS iX™ and How Can It Benefit Your Business?

The ARTAS iX™ robotic hair restoration system is an advanced hair restoration system that combines robotic and artificial intelligence (AI) technology for a cutting-edge hair transplantation system. A lightweight, seven-axis robotic arm offers optimal dexterity, while an advanced multi-camera stereoscopic vision system with 44-micron resolution enables optimal accuracy. Machine learning and AI technology optimizes repeatability, ensuring the first graft is as accurate and identical to the 3000th graft.  

To start, the physician uses ARTAS iX™ harvesting system, aided by image-guided robotics, to analyze and select appropriate grafts from the patient’s donor area. The device’s machine learning and AI technology helps to determine the most viable hair for transplant. Once the system has identified a viable follicle for grafting, the physician then dissects the follicular units with precision using intuitive controls and intelligent algorithms. These help to remove the grafts at an appropriate angle and depth that conserves the natural look of the patient’s donor area. Next, the patented proprietary ARTAS iX™ system identifies and protects existing permanent hair when analyzing the hair growth pattern and angles to determine the recipient site for the most natural-looking outcome. Throughout each treatment, the ARTAS iX™ recognizes and learns new patterns to improve future transplantation procedures.  

Business Benefits: How ARTAS iX™ Can Benefit Your Clinic

Demand for hair restoration procedures is expected to stand strong with a potential target market of about 80 million Americans —a quarter of the American population. An approximate 29 million men are concerned about hair loss, 9.7 million of which are specifically interested in an ARTAS procedure. The hair restoration market poses a significant opportunity for clinics that are properly equipped with a state-of-the-art device alongside business support.  

Introducing the ARTAS iX™ hair restoration platform into your practice is a clear choice, especially true for those hair restoration businesses with a higher patient turnover rate that need to offer the same precise results over and over. The ARTAS iX™ system’s patented dissection and robotics reduce the risks of scarring while accelerating the process and ensuring grafts remain healthy and undamaged from harvesting to implantation. With a well-established, high patient satisfaction rate, the outcomes available through the ARTAS iX™ system is documented with a lineup of high-quality before-and-after images.  

Ready to get started with an ARTAS IX™ robotic hair restoration system? Contact a Venus Concept expert today using the button below.

July 28, 2026
TORONTO, July 28, 2026 (GLOBE NEWSWIRE) -- Venus Concept Inc. (“Venus Concept” or the “Company”), a global medical aesthetic technology leader, today announced it has entered into an exclusive distribution agreement with HIRONIC Co. Ltd. (“HIRONIC”), a KOSDAQ listed South Korean company specializing in medical aesthetic devices, pursuant to which the Company acquires the exclusive right to distribute HIRONIC’s Doublo 2.0 device in the United States and Canada. The “New Doublo 2.0” is a synergistic, multi-energy-based medical device platform for the face and body, equipped with two separate handpieces that enables clinics to offer customer Cold Plasma and RF microneedling treatments. The device has received 510(k) certification from the U.S. Food and Drug Administration, and the Company intends to make it available to customers in the United States during 2H 2026. Venus Concept will support future regulatory approval efforts in Canada for the device and any additional handpiece technologies for both regions. “HIRONIC is a global leader in developing innovative medical aesthetic technologies and we are excited for the new partnership, starting with the Doublo x Venus Signature Edition,” said Rajiv De Silva, Chief Executive Officer of Venus Concept. “With this device, we look forward to offering our customers an innovative, exclusive Cold Plasma and RF Microneedling platform. By combining these complementary technologies, the platform delivers synergistic effects from the epidermis to the dermis, enabling comprehensive skin rejuvenation by addressing multiple skin concerns and enhancing overall skin revitalization. The Doublo also complements our existing portfolio by enhancing the range of treatment modalities for a customizable treatment plan to address each patient’s skin needs. We aim to expand our partnership in the future to bring to our customers additional new and novel technologies from HIRONIC, once regulatory approvals have been obtained.” About Venus Concept Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reaches over 60 countries and 9 direct markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus NOVA, Venus Versa, Venus Versa PRO, Venus Bliss, Venus Bliss MAX, Venus Viva, Venus Viva MD, Venus Legacy, Venus Velocity, Venus Epileve and AI.ME. Venus Concept's hair restoration systems include NeoGraft® and the ARTAS iX® Robotic Hair Restoration system. Venus Concept is backed by Madryn Asset Management, a leading healthcare investment firm that provides capital to innovative growth-stage healthcare companies offering unique and transformative products and technologies. Investor Relations Contact: Damian Yeung, CPA investorrelations@venus.ai View Full Article
May 22, 2026
Skin Cancer Awareness Month highlights prevention and early detection. Learn how dermatologists support care with advanced tools and treatments.
May 22, 2026
Skin cancer radiotherapy improves treatment precision and patient outcomes. Learn how dermatology clinics use it in modern care plans.